Daptomycin > 6 mg/kg/day in complex bone and joint infection

ISRCTN ISRCTN14244698
DOI https://doi.org/10.1186/ISRCTN14244698
Secondary identifying numbers N/A
Submission date
26/01/2016
Registration date
28/01/2016
Last edited
30/09/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Bone and joint infections (BJI) result from a host of different causes, can have very different symptoms and prognoses and need to be treated in different ways. Some, such as uncomplicated childhood osteomyelitis (a bone infection), can be very successfully treated with a short course of antibiotics. In contrast, in some situations such as chronic implant-associated BJI, the pathogen (agent causing the infection) is difficult to eradicate, meaning it is likely to come back despite surgery and prolonged intravenous antibiotic therapy (fed though a drip). In such cases, team-work in specialist hospitals (or tertiary care centers) is required to determine how best to treat the patient to avoid failure, long-lasting disability and risk of amputation. The choice of antimicrobial therapy is also challenging, due to bone diffusion (the antibiotic diffusing into bone tissue), having to use antibiotics that work against bacterial biofilms (that is, bacteria that can stick to surfaces, such as bone), antibiotic resistance and the high risk of severe adverse events (SAE) (side effects). Consequently, off-label use of recently developed antimicrobials, such as daptomycin, is frequently required as salvage therapy (therapy for a condition that doesn’t respond to standard therapy) in complex BJI. This study looks at the safety of daptomycin and how successful it is at treating BJI.

Who can participate?
Adults with complex BJI.

What does the study involve?
Each participant is given high doses (>6 mg/kg/day) of daptomycin for as long as is deemed necessary but the physician. Each patient is then followed up to see if the treatment worked and whether they suffered any serious side effects.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Hospices Civils de Lyon (France)

When is the study starting and how long is it expected to run for?
January 2011 to July 2013

Who is funding the study?
Hospices Civils de Lyon (France)

Who is the main contact?
Professor Tristan Ferry

Contact information

Prof Tristan Ferry
Scientific

Service de Maladies Infectieuses
Hôpital de la Croix-Rousse
93 grande rue de la Croix-Rousse
Lyon
69004
France

Study information

Study designCohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleDaptomycin > 6 mg/kg/day in complex bone and joint infection: prospective cohort study in a regional reference center
Study objectivesSafety and efficacy of daptomycin in patients with complex bone and joint infection
Ethics approval(s)Committee for the Protection of Persons Sud Est III (CPP Sud Est III), ref: QH 20/2014
Health condition(s) or problem(s) studiedComplex bone and joint infection
InterventionA prescription of high doses (>6 mg/kg/day) of daptomycin for complex bone and joint infection. There is only one arm. The total duration is based on the physician decision, and the follow up is based on the usual clinical practice.
Intervention type
Primary outcome measureRate of treatment failure that occurred either during the treatment of after the discontinuation of the treatment. Factors associated with treatment failure were determined on univariate Cox analysis and Kaplan-Meier curves.
Secondary outcome measuresOccurence of serious adverse events
Overall study start date01/01/2011
Completion date01/07/2013

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants43
Key inclusion criteriaPatients with complex BJI managed in the trial participating centre and for whom the need for a treament with daptomycin has been validated in a multidisciplinary meeting
Key exclusion criteriaN/A
Date of first enrolment01/01/2011
Date of final enrolment01/07/2013

Locations

Countries of recruitment

  • France

Study participating centre

Hospices Civils de Lyon
69004
France

Sponsor information

Hospices Civils de Lyon
Hospital/treatment centre

Quai des Celestins
Lyon
69000
France

ROR logo "ROR" https://ror.org/01502ca60

Funders

Funder type

Hospital/treatment centre

Hospices Civils de Lyon

No information available

Results and Publications

Intention to publish date29/02/2016
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planThe article has been accepted for publication in BMC Infectious Disease, but the editor would like us to register this trial before publication
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 17/02/2016 Yes No

Editorial Notes

18/02/2016: Publication reference added.